Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -3,6x - -3,9x | -3,7x |
| Selected Fwd EBIT Multiple | -5,8x - -6,4x | -6,1x |
| Fair Value | $2,78 - $3,06 | $2,92 |
| Upside | 20,7% - 33,2% | 27,0% |
| Benchmarks | Ticker | Full Ticker |
| Agilent Technologies, Inc. | A | NYSE:A |
| AbCellera Biologics Inc. | ABCL | NasdaqGS:ABCL |
| WuXi Biologics (Cayman) Inc. | WXIB.F | OTCPK:WXIB.F |
| Lonza Group AG | LZAG.F | OTCPK:LZAG.F |
| Bristol-Myers Squibb Company | BMY | NYSE:BMY |
| Codexis, Inc. | CDXS | NasdaqGS:CDXS |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| A | ABCL | WXIB.F | LZAG.F | BMY | CDXS | ||
| NYSE:A | NasdaqGS:ABCL | OTCPK:WXIB.F | OTCPK:LZAG.F | NYSE:BMY | NasdaqGS:CDXS | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 8.2% | NM- | 37.1% | 5.7% | 10.1% | NM- | |
| 3Y CAGR | 3.2% | NM- | 13.1% | 12.7% | 4.7% | NM- | |
| Latest Twelve Months | 8.8% | -27.9% | 16.6% | -11.3% | 33.0% | -55.4% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 22.3% | -263.1% | 26.6% | 20.6% | 19.5% | -49.4% | |
| Prior Fiscal Year | 20.7% | -623.8% | 23.1% | 20.3% | 19.2% | -78.1% | |
| Latest Fiscal Year | 23.7% | -980.7% | 24.6% | 18.4% | 20.4% | -98.3% | |
| Latest Twelve Months | 22.2% | -1257.0% | 24.6% | 18.4% | 23.3% | -134.4% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 5.10x | 2.83x | 4.75x | 6.66x | 2.84x | 3.76x | |
| EV / LTM EBITDA | 19.3x | -0.3x | 15.2x | 24.5x | 7.1x | -3.0x | |
| EV / LTM EBIT | 22.9x | -0.2x | 19.4x | 36.2x | 12.2x | -2.8x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -0.2x | 19.4x | 36.2x | ||||
| Historical EV / LTM EBIT | -118.2x | -6.9x | -2.2x | ||||
| Selected EV / LTM EBIT | -3.6x | -3.7x | -3.9x | ||||
| (x) LTM EBIT | (67) | (67) | (67) | ||||
| (=) Implied Enterprise Value | 238 | 251 | 264 | ||||
| (-) Non-shareholder Claims * | 3 | 3 | 3 | ||||
| (=) Equity Value | 242 | 254 | 267 | ||||
| (/) Shares Outstanding | 82.8 | 82.8 | 82.8 | ||||
| Implied Value Range | 2.92 | 3.07 | 3.22 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 2.92 | 3.07 | 3.22 | 2.30 | |||
| Upside / (Downside) | 26.8% | 33.3% | 39.9% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A | ABCL | WXIB.F | LZAG.F | BMY | CDXS | |
| Enterprise Value | 33,652 | (16) | 89,226 | 43,546 | 135,772 | 187 | |
| (+) Cash & Short Term Investments | 1,486 | 605 | 10,710 | 1,711 | 11,782 | 60 | |
| (+) Investments & Other | 135 | 82 | 2,400 | 123 | 2,030 | 3 | |
| (-) Debt | (3,495) | (68) | (4,940) | (5,228) | (51,271) | (59) | |
| (-) Other Liabilities | 0 | 0 | (3,658) | (60) | (59) | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 31,778 | 603 | 93,737 | 40,092 | 98,254 | 191 | |
| (/) Shares Outstanding | 283.9 | 298.5 | 4,068.7 | 70.6 | 2,035.1 | 82.8 | |
| Implied Stock Price | 111.92 | 2.02 | 23.04 | 567.58 | 48.28 | 2.30 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 7.20 | 0.82 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 111.92 | 2.02 | 3.20 | 689.88 | 48.28 | 2.30 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 7.20 | 0.82 | 1.00 | 1.00 | |